Clinical Trials Logo

Clinical Trial Summary

The use of volatile anesthetics in cardiac anesthesia is very common, because of their cardioprotective effects and their ability to ensure a sufficient depth of anesthesia. In line with the development of fast track concepts in cardiac anesthesia, volatile anesthetics are widely used to avoid a delayed recovery from cardiac surgery and anesthesia. Volatile anesthetics are delivered from calibrated vaporizers in the anesthesia machine or the cardiopulmonary bypass machine (during extracorporeal circulation).

Isoflurane and Sevoflurane are the most commonly used volatile anesthetics in patients undergoing cardiopulmonary bypass (CPB). The vaporizer of the anesthetics is on the cardiopulmonary bypass machine and the volatile agent is blended with air and oxygen. Until now, the pharmacokinetics of halothane, enflurane, isoflurane and desflurane during CPB have been described.

Sevoflurane might be of advantage because of additional myocardial protective effects during cardiac anesthesia and cardiopulmonary bypass. However, the pharmacokinetics of sevoflurane during CPB have not been investigated so far, although its being used at many hospitals.

The investigators will conduct a randomized prospective study with either sevoflurane or isoflurane during cardiopulmonary bypass surgery. The study will help to answer the questions about the possible cardioprotective effects of the widely used volatile anesthetics and the hemodynamic stability during cardiopulmonary bypass. Knowing the pharmacokinetics of these drugs allows the anesthesiologist to titrate the volatile anesthetics more precise.

The investigators hypothesizes that the maximal postoperative increase in troponin T will be smaller in the sevoflurane group than in the isoflurane group. The investigators hypothesizes that the total amount of noradrenaline needed during the entire period of cardiopulmonary bypass will be smaller in the sevoflurane group than in the isoflurane group. The investigators hypothesizes that kinetics of washin and washout at the CPB will be faster in the sevoflurane group than in the isoflurane group. The investigators hypothesizes that the time to extubation, respectively the length of stay in intensive care unit and hospital is shorter in the sevoflurane group than in the isoflurane group.


Clinical Trial Description

Endpoints Primary Endpoint: Troponin

The study will compare the maximum postoperative troponin levels in the isoflurane and sevoflurane groups as a direct quantitative marker of damaged myocardial cells. Maximum troponin levels should be reached within the first 24 hours after surgery.

Secondary Endpoints:

A) Hemodynamic stability during on-pump

The investigators will compare the hemodynamic stability during CPB between the isoflurane and sevoflurane group. Therefore the total dosage of noradrenaline used during the surgery will be measured.

B) Washin and Washout Kinetic

Kinetics of washin and washout of sevoflurane and isoflurane during CPB will be investigated and described.

C) Extubation time and length of stay in the intensive care and in hospital

Time to extubation and the length of stay in intensive care unit and in hospital will be documented.

D) Mortality after 30 days

The mortality after 30 days will also be monitored. If the patient is no more in the hospital a phone call will be made. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01601795
Study type Interventional
Source University Hospital, Basel, Switzerland
Contact
Status Completed
Phase Phase 4
Start date July 2012
Completion date January 2014

See also
  Status Clinical Trial Phase
Recruiting NCT00989508 - Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy Phase 2/Phase 3
Not yet recruiting NCT04570514 - Optimized Cardioprotection Therapy in Obese Subjects With AMI
Active, not recruiting NCT01857414 - Effect of RIC on Clinical Outcomes in STEMI Patients Undergoing pPCI N/A
Completed NCT02342522 - Effect of Remote Ischaemic Conditioning on Clinical Outcomes in STEMI Patients Undergoing PPCI (CONDI2/ERIC-PPCI) N/A
Active, not recruiting NCT05462730 - Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction Phase 2
Completed NCT04397939 - Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19
Withdrawn NCT02098629 - Concomitant Milrinone and Esmolol Treatment in Patients With Acute Myocardial Infarction Phase 1/Phase 2
Completed NCT00586820 - Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI Phase 2
Completed NCT02390674 - Ciclosporin to Reduce Reperfusion Injury in Primary PCI Phase 2
Completed NCT00865722 - Remote Postconditioning in Patients With Acute Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention (PCI) Phase 2/Phase 3
Recruiting NCT01307371 - Cell Therapy in Diabetic Patients With ST-Segment Elevation Myocardial Infarction(STEMI) Phase 1
Completed NCT01379261 - Efficacy of Endovascular Catheter Cooling Combined With Cold Saline for the Treatment of Acute Myocardial Infarction Phase 2/Phase 3
Completed NCT00881686 - Myocardial Protection With Adenosine Preconditioning Phase 1/Phase 2
Completed NCT00484575 - Inhaled Sevoflurane Compared to Intravenous Sedation Post Coronary Artery Bypass Grafting Phase 1/Phase 2
Recruiting NCT03995732 - Efficacy and Safety Evaluation of PC-SOD for Injection in Reducing Myocardial Reperfusion Injury Phase 2
Recruiting NCT05775380 - The Role of Pioglitazone in Vascular Transcriptional Remodeling Phase 4
Completed NCT06450912 - Wall Strain Index Ratio as a Biomarker for Mechanical Complication of Hemorrhagic Myocardial Infarction
Completed NCT05354648 - Effects of Hypoxic-hyperoxic Preconditioning in Cardio-surgical Patients N/A
Completed NCT01354808 - ACCEL-LOADING-ACS Study Phase 4
Completed NCT01483755 - Delayed Postconditioning Phase 2